信迪利单抗联合改良DCF方案治疗晚期胃癌的临床研究  

Clinical study of Cindilimab combined with modified DCF regimen in the treatment of advanced gastric cancer

作　　者：卫春燕 宋丽丽 WEI Chunyan;SONG Lili(Department of Pharmacy,Shanghai Fengxian District Central Hospital,Shanghai 201400,China)

机构地区：[1]上海市奉贤区中心医院药剂科,上海201400

出　　处：《检验医学与临床》2022年第14期1970-1974,共5页Laboratory Medicine and Clinic

摘　　要：目的观察信迪利单抗联合改良DCF方案治疗晚期胃癌的疗效,及其对Th1/Th2漂移的影响。方法选择2019-2020年在该院治疗的晚期胃癌患者86例为研究对象,按照随机数字法分为观察组和对照组,每组各43例。对照组予以改良DCF方案治疗,观察组在对照组的基础上予以信迪利单抗治疗。观察两组治疗后的疗效及不良反应,两组治疗前后癌胚抗原(CEA)、糖类抗原(CA)199、CA242、CD168、CD151、CD9、CD63、干扰素(IFN)-γ、白细胞介素(IL)-12、IL-9和IL-13水平的变化。结果观察组的客观有效率和疾病控制率分别为58.14%和88.37%,明显高于对照组的32.56%和65.12%,差异有统计学意义(χ^(2)=4.692,P<0.05;χ^(2)=5.277,P<0.05)。两组肝功能异常、骨髓抑制、蛋白尿、腹泻、输液反应和肺炎发生率比较,差异无统计学意义(P>0.05)。两组治疗前CEA、CA242、CA199、CD168、CD151、CD9、CD63、IFN-γ、IL-12、IL-9和IL-13水平比较,差异无统计学意义(P>0.05);治疗后两组的CEA、CA242、CA199、CD168、CD151、IL-9和IL-13水平均较治疗前明显降低,差异有统计学意义(P<0.05);治疗后,两组CD9、CD63、IFN-γ和IL-12水平较治疗前明显升高,差异有统计学意义(P<0.05);治疗后,观察组以上各项指标的降低和升高水平较对照组更明显,差异有统计学意义(P<0.01)。结论信迪利单抗联合改良DCF方案治疗晚期胃癌的疗效显著,与信迪利单抗能够改善Th1/Th2漂移有关。Objective To observe the efficacy of Cindilimab combined with modified DCF regimen in the treatment of advanced gastric cancer and its impact on Th1/Th2 drift.Methods A total of 86 patients with advanced gastric cancer treated in Shanghai Fengxian District Central Hospital from 2019 to 2020 were randomly divided into observation group and control group,with 43 cases in each group.The control group was treated with modified DCF regimen,and the observation group was treated with Cindilimab on the basis of the control group.The efficacy and adverse reactions were observed in the two groups.The levels of carcinoembryonic antigen(CEA),carbohydrate antigen(CA)199,CA242,CD168,CD151,CD9,CD63 and interferon(IFN)-γ,interleukin(IL)-12,IL-9 and IL-13 were compared in the two groups before and after treatment.Results The objective response rate and disease control rate in the observation group were 58.14%and 88.37%respectively,which were significantly higher than 32.56%and 65.12%in the control group(χ^(2)=4.692,P<0.05;χ^(2)=5.277,P<0.05).There was no significant difference on the incidence rates of abnormal liver function,bone marrow suppression,proteinuria,diarrhea,infusion reaction and pneumonia between the two groups(P>0.05).The levels of CEA,CA242,CA199,CD168,CD151,CD9,CD63,IFN-γ,IL-12,IL-9 and IL-13 had no difference between the two groups before treatment,after treatment the levels of CEA,CA242,CA199,CD168,CD151,IL-9 and IL-13 in the two groups were significantly lower than those before treatment(P<0.05),and the levels of CD9,CD63,IFN-γand IL-12 levels were significantly higher than those before treatment(P<0.05),the decreased and increased levels in the observation group were more obvious than those in the control group(P<0.05).Conclusion The efficacy of Cindilimab combined with modified DCF regimen in the treatment of advanced gastric cancer is obvious,which relates to the improvement of Th1/Th2 drift by Cindilimab.

关 键 词：晚期胃癌 信迪利单抗 改良DCF方案 TH1/TH2漂移 靶向治疗 

分 类 号：R735.2[医药卫生—肿瘤]